The NAD+ challenge: Harnessing immune-mediated tumor control without fueling the enemy [0.03%]
NAD+的挑战：利用免疫介导的肿瘤控制而不去养敌.emplace趙康琪emplace
Eryn Zuiker,Emily A Hemann,Matthew E Long
Eryn Zuiker
Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses [0.03%]
靶向IL-10和PD-（L）1途径的双特异性抗PD-L1 / IL-10-抓抗体可增强T细胞反应
Latika Singh,Natalia Zabavnik,Sambasivan Venkatasubramanian et al.
Latika Singh et al.
Immune checkpoint inhibitors (ICIs) demonstrate clinical benefits with durable responses but only in a subset of patients with cancer. Understanding the mechanisms that limit T cell-mediated cytotoxicity of tumor cells and developing new th...
Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision [0.03%]
循环miRNA在胶质母细胞瘤监测中的应用：从生物流体到临床决策
Arthur Leclerc,Evelyne Emery,Guénaëlle Levallet
Arthur Leclerc
Gliomas, particularly glioblastoma (GBM), remain highly lethal brain tumors with limited treatments. MRI-based monitoring lacks specificity in distinguishing progression from treatment effects. Circulating microRNAs (miRNAs), small non-codi...
Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma [0.03%]
表观遗传抑制剂联合靶向治疗H3K27突变弥漫内皮中间瘤诱导细胞周期共抑制
Zili Zhen,Qiang Gao,Yong Ai et al.
Zili Zhen et al.
Diffuse midline glioma (DMG) is an aggressive malignancy driven by the H3K27M oncohistone, leading to global epigenetic dysregulation and limited efficacy of single-agent epigenetic therapies. We previously observed clinical benefit from an...
Optimizing oncolytic reovirus therapy in hepatocellular carcinoma: A single dose enhances immune modulation and tumor delivery [0.03%]
溶瘤重链病毒治疗肝细胞癌的优化：单剂量增强免疫调节和肿瘤递送
Emma J West,Karen J Scott,Adel Samson
Emma J West
ICAM1-targeted costimulation extends HER2 CAR T cytotoxicity to HER2-low and HER2-negative tumors through synergy with TCR signaling [0.03%]
ICAM1靶向共刺激通过与TCR信号的协同作用将HER2 CAR T细胞的细胞毒性扩展到HER2低表达和HER2阴性肿瘤中
Yogindra Vedvyas,Yanping Yang,Aroshi Mitra et al.
Yogindra Vedvyas et al.
Autologous T cells engineered to express a HER2 chimeric antigen receptor (CAR) have shown limited clinical efficacy. To broaden antitumor activity, we co-expressed a chimeric costimulatory receptor (CCR) targeting ICAM1 (ICCR) in HER2 CAR ...
Ziliang Huang,Yingxiao Wang
Ziliang Huang
Unmasking Wnt-driven HCC: Inhibiting SMYD2 to overcome immune resistance [0.03%]
揭开Wnt驱动的肝细胞癌面纱：抑制SMYD2以克服免疫耐药性
Xiupeng Chen,Allison M Keeler,Joae Qiong Wu
Xiupeng Chen
Oncolytic adenovirus incorporating TetO sites in the E1A promoter for controlled replication in TetR-expressing mesenchymal stem cells [0.03%]
含四环素控制元件的条件复制型肿瘤选择性溶瘤腺病毒 системы
Ramon Alemany,Silvia Torres-Manjon,Laia Traveset et al.
Ramon Alemany et al.
Oncolytic viruses are therapeutic agents that combine self-amplification, lytic activity, and immunostimulatory properties. However, their systemic administration is limited by inefficient tumor delivery. Although mesenchymal stem cell (MSC...
Arming oncolytic Coxsackievirus B3 with Neoleukin-2/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation [0.03%]
武装的肿瘤溶瘤性柯萨奇病毒B3与Neoleukin-2/15结合可增强结直肠癌的生长抑制作用并激活T细胞
Leslie Elsner,Maxim Girod,Ahmet Hazini et al.
Leslie Elsner et al.
Oncolytic viruses (OVs) represent an emerging class of cancer immunotherapeutics. Arming OVs with immunomodulatory transgenes is a promising strategy to reshape the tumor microenvironment (TME) and enhance therapeutic efficacy. We developed...